Takeda Head Admits Firm Behind In Replacing Patent-Losing Blockbusters
This article was originally published in PharmAsia News
CEO says the near future for overcoming patent losses of key drugs is not rosy, due in part to a gap between expirations and getting well-selling substitutes to market.
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.